<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459900</url>
  </required_header>
  <id_info>
    <org_study_id>M-20110071</org_study_id>
    <nct_id>NCT01459900</nct_id>
  </id_info>
  <brief_title>Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial</brief_title>
  <acronym>ReSET</acronym>
  <official_title>Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionshospitalet Silkeborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Randers Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Jutland Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind, randomized and sham controlled study is to determine
      whether renal denervation in terms of catheter based ablation in the renal arteries is
      effective in lowering blood pressure in patients with treatment resistant hypertension. The
      blood pressure lowering effect will be evaluated by 24 hours ambulatory blood pressure
      measurement at baseline and after 1, 3 and 6 months of follow up. Secondary end point
      evaluation concerns hemodynamic measures using echocardiography, applanation tonometry and
      forearm plethysmography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>daytime systolic blood pressure assessed by 24 hours ambulatory BP measurement</measure>
    <time_frame>3 months follow up</time_frame>
    <description>Changes in mean daytime systolic BP after 3 months is compared between groups. Also the proportion of responders versus nonresponders after 3 months is compared between groups, responders being defined as A) a minimum decrease in daytime systolic BP of 10 mmHg analysis together with and unchanged/increased number of antihypertensive drugs, or B) a decrease in daytime systolic BP of 0-10 mmHg together with a reduced number of antihypertensive drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ambulatory 24 hours BP measurements</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Systolic, diastolic and mean Blood Pressures at different time points. Daytime and night time BP, dipping status, morning BP surge and BP variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>Coronary flow reserve (LAD), Diastolic and Systolic ventricular function. LV hypertrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>1 months</time_frame>
    <description>Biomarkers concerning renal sodium excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Applanation tonometry</measure>
    <time_frame>6 months</time_frame>
    <description>Pulse wave velocity, augmentation index, central BP estimates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>forearm plethysmography</measure>
    <time_frame>6 months</time_frame>
    <description>Forearm minimum vascular resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal artery ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal artery ablation</intervention_name>
    <description>Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.</description>
    <arm_group_label>Renal artery ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal angiography</intervention_name>
    <description>Renal angiography by femoral access.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic daytime ambulatory BP at least 145 mmHg and compliance to a minimum of 3
             antihypertensive drugs, including a diuretic, or in case of diuretic intolerance at
             least 3 nondiuretic antihypertensive drugs.

        Exclusion Criteria:

          -  Pregnancy

          -  Non compliance

          -  Heart Failure (NYHA 3-4)

          -  LV ejection fraction &lt; 50 %

          -  Renal insufficiency (eGFR&lt;30)

          -  Unstable coronary heart disease

          -  Coronary intervention within 6 months

          -  Myocardial infarction within 6 months

          -  Claudication

          -  Orthostatic syncope within 6 months

          -  Secondary Hypertension

          -  Permanent atrial fibrillation

          -  Significant Heart Valve Disease

          -  Clinically Significant abnormal electrolytes, haemoglobin, Liver enzymes, TSH

          -  Second and third degree heart block

          -  Macroscopic haematuria

          -  Proximal significant coronary stenosis

          -  Renal artery anatomy not suitable for renal artery ablation (Stenosis, small diameter
             &lt; 4 mm, length &lt; 2 cm, multiple renal arteries, severe calcifications)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole N Mathiassen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Dep. Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2011</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Ole Norling Mathiassen</investigator_full_name>
    <investigator_title>Dr.med</investigator_title>
  </responsible_party>
  <keyword>Treatment Resistant Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

